Publications by authors named "Tamara Isermann"

Claim this Profile
E
Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.
Tamara Isermann, Kim Lucia Schneider, Florian Wegwitz, Tiago De Oliveira, Lena-Christin Conradi

Cell Death Differ· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS inhibitors: resistance drivers and combinatorial strategies.
Tamara Isermann, Christine Sers, Channing J Der, Bjoern Papke

Trends Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.
Tamara Isermann, Kim Lucia Schneider, Florian Wegwitz, Tiago De Oliveira, Lena-Christin Conradi

bioRxiv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan.
Joshua Blume, Luisa Claus, Tamara Isermann, Antje Dickmanns, Lena-Christin Conradi

Cell Cycle· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity.
Tamara Isermann, Özge Çiçek Şener, Adrian Stender, Luisa Klemke, Nadine Winkler

Nat Commun· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis